The strong performance prompted the company to raise its full-year sales guidance, signaling renewed momentum in its core markets. The heart devices company reported sales of $1.53 billion on Thursday after hours, beating the consensus of $1.49 billion and within the management guidance of $1.45 billion-$1.53 billion.
Sales grew 11.9% or 10.6% adjusted, with strength across all product groups. Edwards Lifesciences reported adjusted earnings of 67 cents, beating the consensus of 62 cents and the management guidance of 59-65 cents per share.
Also Read: Court Nixes Jury Award Over Medtronic’s Heart Valve Infringement Claim
The company reported Transcatheter Aortic Valve Replacement (TAVR) sales of $1.1 billion, marking an increase of 8.9% (or 7.8% on a constant currency basis). The company said that TAVR growth for the quarter surpassed their expectations.
Transcatheter Mitral and Tricuspid Therapies (TMTT) segments achieved second-quarter sales of $134.5 million, demonstrating a year-over-year growth of 61.9%, or more than 57.1% on a constant currency basis.
In the Surgical segment, second-quarter global sales reached $267 million, an increase of 7.7% over the prior year, or 6.8% on a constant currency basis.
Outlook
“We are pleased to report strong second quarter results that ...
